natgillin/translations-raw huggingface dataset:
Treat heart conditions or lower blood pressure (e.g. bisoprolol, digoxin, diltiazem, felodipine, nicardipine, nifedipine, propranolol, verapamil)
zdravljenje srčnih bolezni ali za znižanje krvnega tlaka (npr. bisoprolol, digoksin, diltiazem, felodipin, nikardipin, nifedipin, propranolol, verapamil)
Treat pain (e.g. fentanyl, tramadol)
zdravljenje bolečin (npr. fentanil, tramadol)
treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.
za zdravljenje sekundarnega hiperparatiroidizma pri bolnikih z resnim obolenjem ledvic, ki za očiščenje odpadnih snovi iz krvi potrebujejo dializo.
Treat sleep disorders (e.g. zolpidem)
zdravljenje motenj spanja (npr. zolpidem)
treat some types of heart attack and severe angina (pain caused by narrowing of the arteries in the heart). treat blood clots in blood vessels that are near the surface of the skin of the legs (superficial- vein thrombosis).
zdravljenje nekaterih oblik srčnega infarkta in hude oblike angine pektoris (bolečine, ki je posledica zoženja arterij v srcu); zdravljenje krvnih strdkov v žilah, ki potekajo blizu površine kože na nogah (povrhnja venska tromboza).
Treat thyroid disorders (e.g. levothyroxine)
zdravljenje bolezni ščitnice (npr. levotiroksin)
Treat with Day 8 dose level and follow with WBC Growth Factors
Zdravite z ravnijo odmerka 8. dne, nato dajte rastne faktorje belih krvnih celic
Treat with insulin or oral hypoglycaemic agents as needed
Zdravite z insulinom ali peroralnimi hipoglikemičnimi zdravili po potrebi.
Treat with same doses as Day 8
Zdravite z enakimi odmerki kot 8. dne
Treated
Zdravljeni
Treated animals must not be handled for at least eight hours after application of the product.
Izogibajte se stiku z zdravljeno živaljo vsaj osem ur po nanosu zdravila.
Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.
Živalim, zdravljenim s tem zdravilom je potrebno tako med posegom in med okrevanjem zagotoviti, da so na toplem, pri konstantni temperaturi.
Treated animals should be kept warm and at a constant temperature, both during the procedure and recovery.
Živalim, zdravljenim s tem zdravilom, je treba med posegom in okrevanjem zagotoviti, da so na toplem, pri stalni temperaturi.
Treated animals should not be allowed to sleep with their owners, especially children, on the day of treatment.
Zdravljene živali naj na dan aplikacije ne spijo pri lastnikih, še posebno ne pri otrocih.
Treated animals should not be used for breeding for 12 weeks after the last administration.
Zdravljene živali niso za razplod 12 tednov po zadnjem dajanju zdravila
Treated Barrett's mucosa length (cm)
Kombinacija difuzorja z optičnimi vlakni/balonaa
Treated cats should not be permitted to sleep with their owners, especially children, on the day of treatment.
Zdravljene mačke na dan nanosa zdravila ne smejo spati pri lastnikih, zlasti ne pri otrocih.
Treated dogs should not be allowed to enter surface water for 48 hours after treatment to avoid adverse effects on aquatic organisms.
Zdravljeni psi naj ne vstopajo v površinske vode 48 ur po nanosu, v izogib neželenim učinkom na vodne organizme.
Treated dogs should not be allowed to enter surface water for 48 hours after treatment to avoid adverse effects on aquatic organisms. (See section 6.6)
Zdravljeni psi naj ne vstopajo v površinske vode 48 ur po nanosu, v izogib neželenim učinkom na vodne organizme (glej poglavje 6.6).
Treated dogs should therefore still be kept away from bitches on heat within the first 6 weeks after initial treatment
Zato moramo pse, ki so prejeli implantat, prvih 6 tednov po začetni uporabi še vedno imeti ločene od psic, ki se gonijo.
Treated dogs should therefore still be kept away from bitches on heat within the first 6 weeks after initial treatment.
Zato moramo pse, ki so prejeli implantat, prvih šest tednov po začetni uporabi še vedno imeti ločene od psic, ki se gonijo.
Treated dogs should therefore still be kept away from bitches on heat within the first 8 weeks after initial treatment.
Zato moramo pse, ki so prejeli implantat, prvih 8 tednov po začetni uporabi še vedno imeti ločene od psic, ki se gonijo.
Treated patients also experienced a mean decrease in urinary glycosaminoglycan excretion of 238 ± 17.8 μg/mg creatinine ( Standard Error [SE]) following 24 weeks of treatment relative to placebo-treated patients.
Zdravljeni bolniki so v primerjavi s placebo skupino po 24 tednih zdravljenja izločali manj glikozaminoglikanov v urinu, in sicer povprečno za 238  17,8 g kreatinina ( standardna napaka [SE – »standard error«]).
Treated patients had a median age of 50 years (range: 18 to 67); 79% of patients were white; 13% were black/African-American; 1% were Asian; 9% were Hispanic or Latino.
Mediana starost zdravljenih bolnikov je bila 50 let (razpon: od 18 do 67 let), 79 % bolnikov je bilo belcev, 13 % bolnikov črncev/Afroameričanov, 1 % bolnikov Azijcev, 9 % bolnikov pa hispanskega ali latinskega porekla.
Treated patients N
zdravljeni bolniki N
Treated subjects (n = 201) had a median age of 56 years (range: 24 to 70); 70% of the subjects were male; 87% were White; 3% were Black; 9% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 19 to 44 kg/m2); 73% had baseline HCV RNA levels greater than 6 log10 IU/mL; 34% had cirrhosis; 63% had HCV genotype 3; 75% were prior relapsers.
Mediana starost zdravljenih oseb (n = 201) je bila 56 let (razpon: 24 do 70); 70 % oseb je bilo moških; 87 % je bilo belcev; 3 % je bilo črncev; 9 % je bilo španskega ali latinskoameriškega porekla; povprečni indeks telesne mase je bil 29 kg/m2 (razpon: 19 do 44 kg/m2); 73 % jih je imelo ravni RNA HCV ob izhodišču višje od 6 log10 i.e./ml; 34 % jih je imelo cirozo; 63 % jih je imelo HCV genotipa 3; 75 % jih je imelo predhodno relaps.
Treated subjects (n = 278) had a median age of 54 years (range: 21 to 75); 54% of the subjects were male; 91% were White; 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 18 to 53 kg/m2); 70% had baseline HCV RNA levels greater than 6 log10 IU/mL; 16% had cirrhosis; 49% had HCV genotype 3.
Mediana starost zdravljenih oseb (n = 278) je bila 54 let (razpon: 21 do 75); 54 % oseb je bilo moških; 91 % je bilo belcev; 5 % je bilo črncev; 11 % je bilo španskega ali latinskoameriškega porekla; povprečni indeks telesne mase je bil 28 kg/m2 (razpon: 18 do 53 kg/m2); 70 % jih je imelo ravni RNA HCV ob izhodišču višje od 6 log10 i.e./ml; 16 % jih je imelo cirozo; 49 % jih je imelo HCV genotipa 3.
Treated subjects (n = 327) had a median age of 54 years (range: 19 to 70); 64% of the subjects were male; 79% were White; 17% were Black; 14% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 18 to 56 kg/m2); 78% had baseline HCV RNA greater than 6 log10 IU/mL; 17% had cirrhosis; 89% had HCV genotype 1 and 11% had HCV genotype 4, 5 or 6.
Mediana starost zdravljenih oseb (n = 327) je bila 54 let (razpon: 19 do 70); 64 % oseb je bilo moških; 79 % je bilo belcev; 17 % je bilo črncev; 14 % je bilo španskega ali latinskoameriškega porekla; povprečni indeks telesne mase je bil 29 kg/m2 (razpon: 18 do 56 kg/m2); 78 % jih je imelo ravni RNA HCV ob izhodišču višje od 6 log10 i.e./ml; 17 % jih je imelo cirozo; 89 % jih je imelo HCV genotipa 1 in 11 % jih je imelo HCV genotipa 4, 5 ali 6.
Treated subjects (n = 419) had a median age of 51 years (range: 19 to 74); 60% of the subjects were male; median body mass index was 25 kg/m2 (range: 17 to 44 kg/m2); the mean baseline HCV RNA level was 6.4 log10 IU/mL; 21% had cirrhosis; 78% had HCV genotype 3; 65% were prior relapsers.
Mediana starost zdravljenih oseb (n = 419) je bila 51 let (razpon: 19 do 74); 60 % oseb je bilo moških; mediani indeks telesne mase je bil 25 kg/m2 (razpon: 17 do 44 kg/m2); povprečna raven RNA HCV ob izhodišču je bila 6,4 log10 i.e./ml; 21 % jih je imelo cirozo; 78 % jih je imelo HCV genotipa 3; 65 % jih je imelo predhodno relaps.
Treated subjects (n = 499) had a median age of 50 years (range: 19 to 77); 66% of the subjects were male; 87% were White; 3% were Black; 14% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 17 to 52 kg/m2); 57% had baseline HCV RNA levels greater than 6 log10 IU/mL; 20% had cirrhosis; 72% had HCV genotype 3.
Mediana starost zdravljenih oseb (n = 499) je bila 50 let (razpon: 19 do 77); 66 % oseb je bilo moških; 87 % je bilo belcev; 3 % je bilo črncev; 14 % je bilo španskega ali latinskoameriškega porekla; povprečni indeks telesne mase je bil 28 kg/m2 (razpon: 17 do 52 kg/m2); 57 % jih je imelo ravni RNA HCV ob izhodišču višje od 6 log10 i.e./ml; 20 % jih je imelo cirozo; 72 % jih je imelo HCV genotipa 3.
Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 19.7% had a body mass index of at least 30 kg/m2; 20.7% had a history of depression or bipolar disorder; 69.2% had IL28B non-CC genotype; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Zdravljeni preiskovanci (N = 305) so bili mediano stari 54 let (razpon: od 19 do 70); 65,2 % je bilo moških; 11,8 % je bilo črncev; 19,7 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 20,7 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 69,2 % jih je imelo genotip IL28B ne-CC; 86,6 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 18,4 % jih je imelo portalno fibrozo (F2) in 17,7 % jih je imelo fibrozo z mostiči (F3).
Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 20.7% had a history of depression or bipolar disorder; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Zdravljeni preiskovanci (N = 305) so bili mediano stari 54 let (razpon: od 19 do 70); 65,2 % je bilo moških; 11,8 % je bilo črncev; 20,7 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 86,6 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 18,4 % jih je imelo portalno fibrozo (F2) in 17,7 % jih je imelo fibrozo z mostiči (F3).
Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 28.4% had a body mass index of at least 30 kg/m2; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 81.8% had IL28B non-CC genotype; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Zdravljeni preiskovanci (N = 380) so bili mediano stari 58 let (razpon: od 21 do 71); 42,1 % jih še ni bilo zdravljenih, 36,1 % jih predhodno ni imelo odziva na pegIFN/RBV; 8,2 % jih je predhodno imelo delen odziv na pegIFN/RBV in 13,7 % jih je predhodno imelo recidiv ob pegIFN/RBV; 70,3 % je bilo moških; 3,2 % je bilo črncev; 28,4 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 14,7 % jih je imelo število trombocitov manj kot 90 x 109/l; 49,7 % jih je imelo albumin manj kot 40 g/l; 86,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 81,8 % jih je imelo genotip IL28B ne-CC; 24,7 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 68,7 % jih je imelo okužbo s HCV genotipa 1a, 31,3 % pa okužbo s HCV genotipa 1b.
Treated subjects (N=419) had a median age of 50 years (range: 19 to 70), 45.8% were male; 4.8% were Black; 9.3% had a history of depression or bipolar disorder; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Zdravljeni preiskovanci (N = 419) so bili mediano stari 50 let (razpon: od 19 do 70), 45,8 % je bilo moških; 4,8 % je bilo črncev; 9,3 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 73,3 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 20,3 % jih je imelo portalno fibrozo (F2) in 10,0 % jih je imelo fibrozo z mostiči (F3).
Treated subjects (N=419) had a median age of 50 years (range: 19 to 70); 45.8% were male; 4.8% were Black; 16.5% had a body mass index of at least 30 kg/m2; 9.3% had a history of depression or bipolar disorder; 79.0% had IL28B non-CC genotype; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Zdravljeni preiskovanci (N = 419) so bili mediano stari 50 let (razpon: od 19 do 70); 45,8 % je bilo moških; 4,8 % je bilo črncev; 16,5 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 9,3 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 79,0 % jih je imelo genotip IL28B ne-CC; 73,3 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 20,3 % jih je imelo portalno fibrozo (F2) in 10,0 % jih je imelo fibrozo z mostiči (F3).
Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 16.2% had a body mass index of at least 30 kg/m2; 15.2% had a history of depression or bipolar disorder; 69.3% had IL28B non-CC genotype; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Zdravljeni preiskovanci (N = 631) so bili mediano stari 52 let (razpon: od 18 do 70); 54,5 % je bilo moških; 5,4 % je bilo črncev; 16,2 % jih je imelo indeks telesne mase vsaj 30 kg/m2; 15,2 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 69,3 % jih je imelo genotip IL28B ne-CC; 79,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 15,4 % jih je imelo portalno fibrozo (F2) in 8,7 % jih je imelo fibrozo z mostiči (F3); 67,7 % jih je imelo okužbo s HCV genotipa 1a; 32,3 % jih je imelo okužbo s HCV genotipa 1b.
treated with a non-fibrin specific agent (primarily streptokinase).
84 % s trombolitikom zdravljenjih bolnikov se je zdravilo s fibrinsko nespecifičnim zdravilom (predvsem streptokinazo).
treated with roflumilast.
roflumilastom.
treating
lečečega
treating a fracture that is related to a disease such as Paget’s disease or cancer.
za zdravljenje zloma, ki je povezan z boleznijo, kot je Pagetova bolezen ali rak.
Treating diarrhoea early is important (see section 4);
Zgodnje zdravljenje driske je pomembno (glejte poglavje 4);
Treating flu: dose for 5 days
Zdravljenje gripe: odmerjanje za5 dni
treating HIV infection
zdravljenje okužbe s HIV.
Treating symptomatic anaemia caused by chronic kidney disease (renal anaemia) in patients on dialysis, or not yet on dialysis.
zdravljenje simptomatske anemije, povzročene s kronično ledvično boleznijo (ledvična anemija) pri bolnikih, ki so na dializi ali se še ne zdravijo z dializo;
Treatme nt in patients with acute STEMI
Zdravljenj e bolnikov z akutnim STEMI
Treatmen t in patients with acute STEMI
Zdravljenj e bolnikov z akutnim STEMI
Treatmen t in patients with unstable angina and non- Q-wave MI
Zdravljenj e bolnikov z nestabilno angino pektoris in MI brez zobca Q
Treatment
Pri sočasni
Treatment
razlika v
treatment
zdravljenja
Treatment (infusion) number
Številka zdravljenja (infuzije)
treatment (weeks)
(kg/m2)
Treatment - Invasive Aspergillosis Study 0041
Zdravljenje – invazivna aspergiloza Študija 0041
Treatment adjustments
Prilagajanje zdravljenja
Treatment after LH surge but before LH peak
Jemanje zdravila po nastopu najvišje ravni LH
Treatment against Isospora should aim to minimize the shedding of oocysts into the environment, thereby reducing the risk for reinfection in groups/kennels with known and recurring Isospora infections.
Zdravljenje zoper Isosporo je namenjeno zmanjšanju izločanja oocist v okolje in s tem zmanjšanju ponovne okužbe v skupinah/zavetiščih z znano in ponavljajočo okužbo z Isosporo.
Treatment and
Preprečevanje in zdravljenje
Treatment and control of gastro-intestinal nematodes in pigs infected with:
Zdravljenje in nadzor gastrointestinalnih nematodov pri prašičih, ki so okuženi z:
Treatment and metaphylaxis of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj goveda (BRD), povzročenih z Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis občutljivih na tulatromicin.
Treatment and metaphylaxis of porcine proliferative enteropathy (ileitis) caused by Lawsonia intracellularis.
Zdravljenje in metafilaksa prašičje proliferativne enteropatije (ileitis), ki jo povzroča Lawsonia intracellularis.
Treatment and metaphylaxis of respiratory infections caused by Mycoplasma gallisepticum in chickens.
Zdravljenje in kontrolno zdravljenje (metafilaksa) okužb dihal, ki jih povzroča Mycoplasma gallisepticum, pri piščancih.
Treatment and metaphylaxis of swine dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed.
Zdravljenje metafilaksa dizenterija pri prašičih, ki jo povzroča Brachyspira Hydosenteriae, v čredah, kjer je bila diagnosticirana bolezen.
Treatment and metaphylaxis of swine dysentery in herds, where the disease has been diagnosed.
Zdravljenje metafilaksa dizenterije pri prašičih v čredah, kjer je bila diagnosticirana bolezen.
Treatment and metaphylaxis of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed.
Zdravljenje in metafilaksa dizenterije pri prašičih, ki jo povzroča Brachyspira Hydosenteriae, v čredah, kjer je bila diagnosticirana bolezen.
Treatment and metaphylaxis of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed.
Zdravljenje metafilaksa dizenterije pri prašičih, ki jo povzroča Brachyspira hyodysenteriae, v čredah, kjer je bila diagnosticirana bolezen.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae in pigs.
Zdravljenje in metafilaksa enzootske pljučnice pri prašičih, ki jo povzročajo občutljivi sevi mikroorganizma Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae in pigs.
Zdravljenje in metafilaksa enzootske pljučnice pri prašičih, ki jo povzročajo občutljivi sevi Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae.
Zdravljenje in metafilaksa enzootske pljučnice pri prašičih, ki jo povzročajo občutljivi sevi mikroorganizma Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae.
Zdravljenje in metafilaksa enzootske pljučnice pri prašičih, ki jo povzročajo občutljivi sevi Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin.
Zdravljenje in metafilaksa prašičje respiratorne bolezni (SRD), povzročene z Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica in Haemophilus parasuis, ki so občutljivi za tildipirozin.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae in Haemophilus parasuis in Bordetella bronchiseptica občutljivih na tulatromicin.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae,Haemophilus parasuis in Bordetella bronchiseptica, občutljivih na tulatromicin.
Treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis in Bordetella bronchiseptica, občutljivih na tulatromicin.
Treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae,Haemophilus parasuis in Bordetella bronchiseptica, občutljivih na tulatromicin.
Treatment and monitoring recommendations*
Priporočila za zdravljenje in spremljanje
Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents 12 to 17 years old with hereditary angioedema (HAE).
Zdravljenje in predoperativno preprečevanje napadov angioedema pri odraslih in mladostnikih, starih 12 do 17 let, z dednim angioedemom (HAE-hereditary angioedema).
Treatment and prevention of flea infestation (Ctenocephalides canis and C. felis.).
Zdravljenje in preprečevanje infestacij z bolhami (Ctenocephalides canis in C. felis).
Treatment and prevention of flea infestation (Ctenocephalides felis).
Zdravljenje in preprečevanje infestacije z bolhami (Ctenocephalides felis)
Treatment and prevention of flea infestation when concurrent prevention of heartworm disease and/or concurrent treatment of nematode infections is indicated.
Zdravljenje in preprečevanje infestacij z bolhami, kadar je indicirano sočasno preprečevanje dirofilarioze in/ali sočasno zdravljenje okužb z nematodi.
Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration.
Zdravljenje in preprečevanje infestacij z bolhami, ki jih povzročajo vrste Ctenocephalides spp. - zdravilo deluje en mesec po enkratnem odmerku.
Treatment and prevention of infestations by fleas (Ctenocephalides felis).
Zdravljenje in preprečevanje bolhavosti (Ctenocephalides felis).
Treatment and prevention of infestations by ticks (Ixodes ricinus).
Zdravljenje in preprečevanje klopavosti (Ixodes ricinus).
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis).
Zdravljenje in preprečevanje infestacije s klopi pri psih (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemophysalis longicornis, Amblyomma americanum in Amblyomma maculatum) in bolhami (Ctenocephalides felis in Ctenocephalides canis).
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis).
Zdravljenje in preprečevanje infestacije s klopi pri psih (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentorvariabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum in Amblyomma. maculatum) in bolhami (Ctenocephalides felis in Ctenocephalides canis).
Treatment and prevention of infestations with fleas and ticks.
Zdravljenje in preprečevanje infestacij z bolhami in klopi.